Oct 15, 2018
The Centers for Medicare & Medicaid Services today issued a proposed rule aimed at increasing drug price transparency and reducing the price of prescription drugs and biological products to consumers b
Apr 12, 2019
The House Ways and Means Committee today approved the Prescription Drug Sunshine, Transparency, Accountability and Reporting Act (H.R. 2113), AHA-supported legislation that would increase transparency with regard to prescription drug pricing.
Apr 9, 2019
AHA letter to Ways and Means Committee on the Prescription Drug Sunshine, Transparency, Accountability and Reporting Act (H.R. 2113.
Apr 2, 2019
A recent report in MobiHealth News explores how well-funded, established startups and fledgling companies alike are finding ways to cut the costs of prescription medications. Their services are targeted to the more than 27 million consumers who are uninsured or underinsured — including the 43…
Feb 14, 2019
Senate Finance Committee Ranking Member Ron Wyden, D-Ore., along with several other Democratic senators, yesterday introduced bills aimed at increasing transparency for prescription drug prices and reducing costs for Medicare Part D enrollees.
Feb 1, 2019
The Department of Health and Human Services’ Office of Inspector General yesterday proposed excluding from safe harbor protection under the Anti-Kickback Statute rebates paid by prescription drug makers to pharmacy benefit managers, Medicare Part D plans and Medicaid managed care organizations.
Jan 18, 2019
Last week, I shared a few areas where we can advance health in America this year, even in a divided Congress. Number one on that list: reining in the skyrocketing costs of prescription drugs.
Jan 15, 2019
The American Hospital Association (AHA), the Federation of American Hospitals (FAH), and the American Society of Health-System Pharmacists (ASHP) released a new report finding that continued rising drug prices, as well as shortages for many critical medications, are impacting patient care and…
Dec 17, 2018
The AHA today voiced support for a Centers for Medicare & Medicaid Services’ proposal to require drug pricing transparency in direct-to-consumer television advertisements and encouraged the agency to “rein in skyrocketing drug prices” for patients and the providers who serve them.